Trial Profile
First-line vinorelbine + cisplatin +/- celecoxib then second-line icotinib +/- celecoxib in patients with advanced NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2014
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Cisplatin; Icotinib; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Feb 2014 New trial record